CTRI/2022/10/046222已完成2 期
An open labelled, multi-center, non-comparative, interventional, prospectiveclinical study to evaluate efficacy and safety of OptimaLiv Capsule in healthy participants.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy males and females with mild to moderate digestive complaints (Healthy individuals will be defined as those who are not taking any medications and do not require continuous medical care and monitoring)
- •2. Ready to provide written consent and follow all the study procedure
排除标准
- •1.Subjects with known tuberculosis, hepatitis B and C, HIV, ischemic heart disease, cancer, kidney failure, chronic liver diseases,
- •2.Subjects having jaundice or any other symptom of active hepatitis
- •3.Subjects with any other investigational product within 1 month prior to randomization.
- •4.Subjects with diabetes mellitus and hypertension taking regular medications
- •5.Pregnant and lactating women
- •6.Subjects with any significant abnormal laboratory parameters
- •7.Known hypersensitivity to any of the ingredients of OptimaLIV Capsules
- •8.Other conditions, which in the opinion of the investigators, make subject unsuitable for enrolment or could interfere with his/her participation in, and completion of the study.
研究者
相似试验
已完成
2 期
Clinical study on ClensicapCTRI/2022/10/046223Transformative Learning Solutions Private Limited
已完成
2 期
Clinical study on Ampop tablet in healthy participants.CTRI/2023/03/050976Transformative Learning Solutions Private Limited
进行中（未招募）
1 期
An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.The medical condition being treated by this protocol is single or recurrent major depressive disorder (MDD), not responding to at least one adequate SSRI treatment, however, the patients being treated should be naïve to any atypical antipsychotic.MedDRA version: 8.0Classification code 10025453EUCTR2005-001737-15-BEV AstraZeneca SA40
进行中（未招募）
不适用
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children.Severe Respiratory Syncytial Virus Infection (RSV)MedDRA version: 17.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-004527-42-Outside-EU/EEAAbbott Laboratories LLC100
招募中
4 期
Clinical trial on replacement of damaged skin in patientsCTRI/2020/02/023205ifeNet Health Inc